Sun Pharmaceutical Industries Limited (Sun Pharma) is among India’s leading pharmaceutical companies. With its current share price at ₹1,782, the company is a prominent player in the healthcare sector, both domestically and globally. Let’s dive into Sun Pharma’s future share price targets and growth potential.
About Sun Pharma
Sun Pharma is one of the largest specialty generic pharmaceutical companies globally. Known for its robust portfolio of generics, specialty drugs, and over-the-counter products, it caters to over 100 markets worldwide.
Company Details
Founded: 1983
Headquarters: Mumbai, India
Sector: Pharmaceuticals
Global Presence: Over 100 countries
Competitors: Dr. Reddy’s, Cipla, Lupin
Promoter Details
Promoter Name
Holding (%)
Dilip Shanghvi & Family
54.48
Public & Institutional Investors
45.52
Sun Pharma Share Price Target 2024
Growth Drivers:
Expansion in specialty drugs and generics.
Focus on innovation and R&D.
Minimum Target: ₹1,850
Maximum Target: ₹1,950
Sun Pharma Share Price Target 2025
Key Catalysts:
Strong global growth in specialty products.
Rising demand for chronic and lifestyle disease treatments.
Minimum Target: ₹2,000
Maximum Target: ₹2,150
Sun Pharma Share Price Target 2026 to 2030
Year
Minimum Target (₹)
Maximum Target (₹)
2026
2,200
2,350
2027
2,400
2,600
2028
2,650
2,850
2029
2,900
3,150
2030
3,200
3,500
Sun Pharma Share Price Target 2035
With advancements in biotechnology and personalized medicine, Sun Pharma is poised for substantial growth by 2035.
Minimum Target: ₹4,500
Maximum Target: ₹5,000
Sun Pharma Share Price Target 2040
By 2040, Sun Pharma’s investments in innovation, market diversification, and R&D are expected to yield impressive returns.
Sun Pharma remains a strong contender for long-term investments due to its consistent innovation, robust global presence, and focus on high-demand healthcare segments.
Disclaimer: Always conduct thorough research or consult a financial advisor before investing in stocks. For more insights, visit moneyphobia.in!
Recent Posts
Abhijeet Dipke Joins Protest at Jantar Mantar, CJP Raises Concerns Over Civil Rights
JPMorgan Invests $24 Million to Boost US Shipbuilding Industry
Offshore Wind Power Faces Fresh Challenges Under Trump Administration Policy
US Gas Prices Edge Higher After Fresh US-Iran Tensions Shake Oil Markets
Reliance Industries Q1 Results 2026: Profit Beats Estimates as Jio and O2C Drive Growth
SBI IPO Allotment Status 2026: How to Check on KFinTech, BSE and NSE
Indian Stocks Show Mixed Earnings as Mideast Worries Trigger Downgrades Says Jefferies - Investing.com
Punjab National Bank stock (INE692A01016): shares firm on latest quarterly results and Indian bankin - AD HOC NEWS
Ahluwalia Contracts (India) Ltd Reports Positive Financial Trend Amid Mixed Quarterly Results - Markets Mojo
Indian Energy Exchange Ltd Reports Record Quarterly Performance Amid Flat Financial Trend - Markets Mojo
Power Grid Corporation of India Q1 Results - Mint
Union Bank of India Q4 Results 2026 - Find Union Bank of India Q4 Earnings Result | UNIONBANK Q4 results - Mint